Wave of new therapies aimed at KRAS-mutant cancers; CAR-T strategy for tackling blood cancers

KRAS, one of the most common genetic mutations in cancer, has long been a tantalizing oncogenic target for drug developers.

September 1, 2023 Check out STAT+

Sponsored By

Molly Ferguson for STAT STAT+ | KRAS, the ideal cancer drug target that became 'undruggable,' takes on a new glow With the approval of Lumakras and Krazati, researchers are starting to gain ground in using a common genetic mutation to counter cancers. By Angus Chen and Bree Iskandar STAT+ | Sly CAR-T strategy evades 'fratricide' problem to aim at all blood cancers A study in mice uses base editing to render healthy blood cells invisible to engineered cancer-killing T cells. By Jason Mast STAT+ | Pharmalittle: Winners and losers from Medicare drug-negotiation list; Novo strikes deal to keep lead in weight-loss drugs Walmart is asking some of its 16,000 pharmacists across the U.S. to voluntarily take pay cuts by reducing work hours in a bid to lower costs. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser